| 1.5 Non-Myeloablative Blood Stem Cell Trans-plantation for Patients with Haematologic Malignancies and Poor Prognosis R Fenk, H Pape, R Kronenwett, F Neumann, R Haas High Dose Therapy and Transplantation of Haemopoietic Stem Cells:(2001), 20, 2002 | | 2002 |
| 103 Therapy-related myeloid neoplasms following treatment with radioiodine TM Schroeder, A Kündgen, N Kröger, U Platzbecker, M Stadler, F Braulke, ... Leukemia Research, S39-S40, 2011 | | 2011 |
| 10th Symposium on Molecular Biology of Hematopoiesis and Treatment of Leukemias and Lymphomas. Hamburg, Germany July 2-6, 1997 NG Abraham, J Adamson, S Asano, G Brittinger, R Haas, S Ikehara, ... Acta Haematologica 98 (1), 1997 | | 1997 |
| 119 UPDATE ON THE MULTICENTER MDS BIOREGISTRY PROJECT OF THE “KREBSHILFE-VERBUNDFORSCHUNGSPROJEKT MDS” OF THE GERMAN MDS STUDY GROUP I Schemenau, C Strupp, M Wulfert, T Schroeder, B Xicoy, A Nusch, ... Leukemia Research, S61-S62, 2015 | | 2015 |
| 121 PERIPHERAL BLOOD (PB) WILMS'TUMOR 1 (WT1) EXPRESSION QUANTIFIED BY A STANDARDIZED EUROPEAN LEUKEMIA NET (ELN)-CERTIFIED ASSAY AS PROGNOSTIC AND MINIMAL RESIDUAL DISEASE … T Schroeder, S Pechtel, M Lamers, A Dienst, E Schuler, E Rachlis, ... Leukemia Research, S62-S63, 2015 | | 2015 |
| 153 Analysis of causes of death in 2297 patients with myelodysplastic syndromes. Data from the Dusseldorf MDS registry K Nachtkamp, R Stark, J Neukirchen, A Kündgen, A Giagounidis, R Haas, ... Leukemia Research, S60, 2011 | 1 | 2011 |
| 160 ANALYSIS OF POSSIBLE BIOMARKERS TO PREDICT RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE A Kuendgen, C Müller-Thomas, M Lauseker, P Urbaniak, T Haferlach, ... Leukemia Research, S82, 2015 | 1 | 2015 |
| 162 THE PRESENCE OF SUBCLONES WITHIN AN ABNORMAL KARYOTYPE IS ASSOCIATED WITH AN INFERIOR PROGNOSIS IN MDS PATIENTS J Neukirchen, B Hildebrandt, AC Nolting, R Haas, U Germing Leukemia Research, S83, 2015 | | 2015 |
| 18F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy? R Zukovs, C Antke, E Mamlins, LM Sawicki, A Mohring, ... BMC Medical Imaging 22 (1), 63, 2022 | 1 | 2022 |
| 2009 Annual Meeting of the American Society of Hematology F Fox, A Kündgen, K Nachtkamp, C Strupp, R Haas, U Germing, ... | | |
| 21. Aplastic Anemia P Schneider, A Bernhard, R Fenk, U Germing, M Aivado, H Pape, R Haas, ... | | |
| 2171 Cataract incidence after total-body irradiation D Zierhut, F Lohr, P Schraube, P Huber, R Haas, W Hunstein, ... International Journal of Radiation Oncology* Biology* Physics 39 (2), 326, 1997 | | 1997 |
| 231 UPDATE OF RESPONSE TO TREATMENT WITH AZACITIDINE AND DECITABINE IN HIGH-RISK MDS PATIENTS FROM THE DUESSELDORF MDS REGISTRY–10 YEARS EXPERIENCE WITH HYPOMETHYLATING TREATMENT J Neukirchen, A Schuck, MC Götte, A Kündgen, G Kobbe, R Haas, ... Leukemia Research, S115-S116, 2015 | | 2015 |
| 245 CHOICE OF THERAPY HAS THE STRONGEST IMPACT ON SURVIVAL IN OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA OR AML AFTER MYELODYSPLASTIC SYNDROME I Rumcheva, J Schemenau, B Hildebrandt, A Kündgen, T Schroeder, ... Leukemia Research, S122, 2015 | | 2015 |
| 264 MMP-9 SERUM LEVEL IN MDS DIAGNOSIS, PROGNOSIS AND DISEASE PROGRESSION CM Wilk, A Kündgen, C Zilkens, R Haas, R Krauspe, U Germing, J Fröbel Leukemia Research, S133, 2015 | | 2015 |
| 295 Validation of the WHO 2008 classification for ‘non-blastic’myelodysplastic syndromes. Lumping or splitting? U Germing, A Maassen, C Strupp, A Kündgen, B Hildebrandt, ... Leukemia Research, S116, 2011 | | 2011 |
| 304 Clinical impact of trisomy 11 in patients with MDS and AML V Klärner, T Schroeder, A Kuendgen, N Safaian, C Weigelt, C Saure, ... Leukemia Research, S120, 2011 | | 2011 |
| 307 A comparison of clinical characteristics and the role of prognostic markers in 1757 MDS patients from Japan, Korea, and Germany A Kuendgen, JH Lee, A Matsuda, T Hata, Y Miyasaki, KH Lee, ... Leukemia Research, S121, 2011 | | 2011 |
| 312 Restratification of IPSS risk groups according to the WPSS identifies patients with myelodysplastic syndromes (MDS) at higher risk J Neukirchen, B Hildebrandt, A Kuendgen, K Nachtkamp, R Haas, ... Leukemia Research, S124, 2011 | 1 | 2011 |
| 317 ASXL1 MUTATION IS ASSOCIATED TO LOWER PLATELET COUNTS AND DECREASED BONE MARROW CELLULARITY IN MDS J Schemenau, B Betz, B Hildebrandt, S Baldus, A Kündgen, J Neukirchen, ... Leukemia Research, S157, 2015 | 1 | 2015 |
